378 related articles for article (PubMed ID: 15501782)
1. Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential.
O'dwyer CA; Reddin K; Martin D; Taylor SC; Gorringe AR; Hudson MJ; Brodeur BR; Langford PR; Kroll JS
Infect Immun; 2004 Nov; 72(11):6511-8. PubMed ID: 15501782
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
[TBL] [Abstract][Full Text] [Related]
3. Assessment of vaccine potential of the Neisseria-specific protein NMB0938.
Sardiñas G; Climent Y; Rodríguez Y; González S; García D; Cobas K; Caballero E; Pérez Y; Brookes C; Taylor S; Gorringe A; Delgado M; Pajón R; Yero D
Vaccine; 2009 Nov; 27(49):6910-7. PubMed ID: 19751688
[TBL] [Abstract][Full Text] [Related]
4. A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.
Pajon R; Buckwalter CM; Johswich KO; Gray-Owen SD; Granoff DM
Vaccine; 2015 Mar; 33(11):1317-1323. PubMed ID: 25662856
[TBL] [Abstract][Full Text] [Related]
5. Induction of immune responses by purified outer membrane protein complexes from Neisseria meningitidis.
Marzoa J; Sánchez S; Costoya L; Diéguez-Casal E; Freixeiro P; Brookes C; Allen L; Taylor S; Gorringe AR; Ferreirós CM; Criado MT
Vaccine; 2012 Mar; 30(13):2387-95. PubMed ID: 21911024
[TBL] [Abstract][Full Text] [Related]
6. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
Bai X; Borrow R
Expert Rev Vaccines; 2010 Oct; 9(10):1203-17. PubMed ID: 20923270
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
Finney M; Vaughan T; Taylor S; Hudson MJ; Pratt C; Wheeler JX; Vipond C; Feavers I; Jones C; Findlow J; Borrow R; Gorringe A
Hum Vaccin; 2008; 4(1):23-30. PubMed ID: 17921703
[TBL] [Abstract][Full Text] [Related]
8. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
Holst J
Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231
[TBL] [Abstract][Full Text] [Related]
9. Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.
Wedege E; Bolstad K; Aase A; Herstad TK; McCallum L; Rosenqvist E; Oster P; Martin D
Clin Vaccine Immunol; 2007 Jul; 14(7):830-8. PubMed ID: 17494638
[TBL] [Abstract][Full Text] [Related]
10. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
[TBL] [Abstract][Full Text] [Related]
11. Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B.
Moe GR; Zuno-Mitchell P; Lee SS; Lucas AH; Granoff DM
Infect Immun; 2001 Jun; 69(6):3762-71. PubMed ID: 11349041
[TBL] [Abstract][Full Text] [Related]
12. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein.
Fletcher LD; Bernfield L; Barniak V; Farley JE; Howell A; Knauf M; Ooi P; Smith RP; Weise P; Wetherell M; Xie X; Zagursky R; Zhang Y; Zlotnick GW
Infect Immun; 2004 Apr; 72(4):2088-100. PubMed ID: 15039331
[TBL] [Abstract][Full Text] [Related]
13. Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease.
Watson PS; Novy PL; Friedland LR
Int J Infect Dis; 2019 Aug; 85():22-27. PubMed ID: 31102824
[TBL] [Abstract][Full Text] [Related]
14. Impact of meningococcal group B OMV vaccines, beyond their brief.
Petousis-Harris H
Hum Vaccin Immunother; 2018 May; 14(5):1058-1063. PubMed ID: 29048985
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
Sanders H; Feavers IM
Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
[TBL] [Abstract][Full Text] [Related]
16. Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.
Matthias KA; Reveille A; Connolly KL; Jerse AE; Gao YS; Bash MC
Vaccine; 2020 Feb; 38(10):2396-2405. PubMed ID: 32037226
[TBL] [Abstract][Full Text] [Related]
17. Proteomic analysis of Neisseria lactamica and N eisseria meningitidis outer membrane vesicle vaccine antigens.
Vaughan TE; Skipp PJ; O'Connor CD; Hudson MJ; Vipond R; Elmore MJ; Gorringe AR
Vaccine; 2006 Jun; 24(25):5277-93. PubMed ID: 16682101
[TBL] [Abstract][Full Text] [Related]
18. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model.
Zhu D; Zhang Y; Barniak V; Bernfield L; Howell A; Zlotnick G
Infect Immun; 2005 Oct; 73(10):6838-45. PubMed ID: 16177362
[TBL] [Abstract][Full Text] [Related]
20. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
